ClinicalTrials.gg
RecruitingNCT05979051Updated Dec 4, 2025

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA)

A Phase 2/3 interventional study of SHR-1703 and Mepolizumab Injection in Eosinophilic Granulomatosis With Polyangiitis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.

02

Conditions studied

  • Eosinophilic Granulomatosis With Polyangiitis

Browse trials for

03

In context

Churg-Strauss Syndrome

61 studies on the registry are indexed under Churg-Strauss Syndrome; 17 are open to participants now.

This study's planned enrollment of 166 is above the median of 66 across 30 interventional studies indexed under Churg-Strauss Syndrome.

Browse Churg-Strauss Syndrome studies →

Lead sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects age 18 years or older;
  2. Diagnosed with EGPA for at least 6 months;
  3. History of relapsing or EGPA;
  4. Stable dose of oral prednisone of ≥7.5 mg/day (but not >50 mg/day) for at least 4 weeks prior to randomization;
  5. If receiving therapy (excluding cyclophosphamide), the dosage must be stable within 4 weeks prior to randomization and during the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with other eosinophilic-related diseases;
  2. Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
  3. Life-threatening EGPA within 3 months prior to randomization;
  4. history within 5 years prior to randomization;
  5. Immunodeficiency;
  6. Uncontrolled hypertension;
  7. Uncontrolled cerebrovascular and cardiovascular disease;
  8. parasitic infection within 6 months prior to randomization;
  9. Active infectious disease requiring clinical treatment within 4 weeks prior to randomization;
  10. Subjects with a dose of oral prednisone of >50 mg/day within 4 weeks prior to randomization;
  11. Oral or intravenous cyclophosphamide therapy within 4 weeks prior to randomization;
  12. Intravenous or subcutaneous immunoglobulin within 12 weeks prior to randomization;
  13. Biological agents or TH2 cytokine inhibitors used within 12 weeks prior to randomization or within 5 half-lives of the drug;
  14. Rituximab used within 6 months prior to randomization;
  15. Surgical plans that might affect the evaluation;
  16. Significant laboratory abnormalities;
  17. Prolonged or other abnormalities with significant safety risk at screening;
  18. History of drug or substance abuse or alcohol abuse within 1 year prior to screening;
  19. Subjects participated another clinical study and received active drug within 30 days or 5 half-lives of the drug prior to screening;
  20. Subjects is pregnant, lactating, or planning to be pregnant;
  21. Subjects have a known history of or intolerance to anti-IL-5 mabs or other biological agents or previous failure of IL-5/IL-5R therapy;
  22. Other conditions unsuitable for participation in the study per investigator judgement.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
166 participants (estimated)

Study arms

  • Experimental
    Treatment group A

    SHR-1703

    Drug: SHR-1703

  • Active comparator
    Mepolizumab Injection

    SHR-1703 Placebo

    Drug: Mepolizumab Injection

Interventions

  • SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.

  • Mepolizumab Injection and Matching Placebo will be administered by Subcutaneous injection in Phase 3

06

What researchers measure

Primary outcomes

  1. Change from baseline in oral glucocorticoid dose (OCS)

    Phase 2

    Time frame: Up to week 12

  2. The Proportion of subjects in EGPA remission

    Phase 3

    Time frame: week 36 and week 48

Secondary outcomes

  1. Change from baseline in oral glucocorticoid dose

    Effectiveness Indicators (Phase 2)

    Time frame: Up to week 24, week 48

  2. The proportion of subjects with OCS dosage ≤5 mg/d

    Effectiveness Indicators (Phase 2)

    Time frame: week 12, week 24, week 48

  3. The proportion of subjects with at least 50% reduction of OCS dosage from baseline

    Effectiveness Indicators (Phase 2)

    Time frame: week 12, week 24, week 48

  4. The Proportion of subjects with EULAR remission

    Effectiveness Indicators (Phase 2)

    Time frame: week 12, week 24, week 48

  5. The Proportion of subjects achieving EULAR remission at week 12 and week 24 of treatment and maintaining it up to week 48

    Effectiveness Indicators (Phase 2)

    Time frame: week 12, week 24, week 48

  6. The Proportion of subjects with EGPA remission

    Effectiveness Indicators (Phase 2)

    Time frame: week 24, week 48

  7. The proportion of subjects achieving EGPA remission within 24 weeks of treatment and maintaining it up to week 48

    Effectiveness Indicators (Phase 2)

    Time frame: week 24, week 48

  8. The proportion of subjects with EGPA relapse

    Effectiveness Indicators (Phase 2)

    Time frame: week 12, week 24, week 48

  9. The time to the first relapse of EGPA

    Effectiveness Indicators (Phase 2)

    Time frame: Up to week 48

  10. The proportion of subjects with Severe relapse of EGPA

    Effectiveness Indicators (Phase 2)

    Time frame: week 12, week 24, week 48

  11. The time of the first Severe relapse of EGPA

    Effectiveness Indicators (Phase 2)

    Time frame: Up to week 48

  12. Changes from baseline in Pre- and post-Bronchodilator FEV1

    Effectiveness Indicators (Phase 2)

    Time frame: Up to week 48

  13. The Proportion of subjects with EULAR remission

    Effectiveness Indicators (Phase 3)

    Time frame: week 36, week 48

  14. The Proportion of subjects with EGPA remission

    Effectiveness Indicators (Phase 3)

    Time frame: week 36, week 48

  15. The Proportion of subjects achieving EULAR remission within 24 weeks of treatment and maintaining it up to week 48

    Effectiveness Indicators (Phase 3)

    Time frame: week 24, week 48

  16. The proportion of subjects achieving EGPA remission within 24 weeks of treatment and maintaining it up to week 48

    Effectiveness Indicators (Phase 3)

    Time frame: week 24, week 48

  17. Cumulative weeks of EGPA remission through week 48, categorized as 0 weeks; >0 to <12 weeks; 12 to <24 weeks; 24 to <36 weeks; or ≥36 weeks

    Effectiveness Indicators (Phase 3)

    Time frame: week 0, week 12, week 24, week 36, week 48

  18. Change from baseline in OCS

    Effectiveness indicators (Phase 3)

    Time frame: Week 24, Week 48

  19. The proportion of subjects with OCS dosage ≤5 mg/d

    Effectiveness indicators (Phase 3)

    Time frame: week 24, week 48

  20. The proportion of subjects with at least 50% reduction of OCS dosage from baseline

    Effectiveness indicators (Phase 3)

    Time frame: week 24, week 48

  21. The Proportion of subjects with EGPA relapse

    Effectiveness indicators (Phase 3)

    Time frame: week 24, week 48

  22. The Proportion of subjects with Severe relapse of EGPA

    Effectiveness indicators (Phase 3)

    Time frame: week 24, week 48

  23. The time to the first relapse of EGPA

    Effectiveness indicators (Phase 3)

    Time frame: Up to week 48

  24. The time of the first Severe relapse occurred of EGPA

    Effectiveness indicators (Phase 3)

    Time frame: Up to week 48

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Dec 2028, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2023
First posted
Aug 7, 2023
StartActual
Nov 16, 2023
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05979051
Responsible party
Sponsor
First posted
Aug 7, 2023
Start date
Nov 16, 2023
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Dec 4, 2025

Study contacts

Siai Sun
Contact
siai.sun@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1703

Start the discussion